Editas Medicine (EDIT) Current Deferred Revenue (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Current Deferred Revenue data on file, last reported at $44.5 million in Q4 2025.

• On a quarterly basis, Current Deferred Revenue fell 26.34% year-over-year to $44.5 million in Q4 2025; TTM through Dec 2025 was $44.5 million, a 26.34% decrease from a year earlier, with the FY2025 full-year figure at $44.5 million, down 26.34% from the prior year.
• Current Deferred Revenue for Q4 2025 stood at $44.5 million, down from $56.2 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for EDIT reached as high as $89.2 million in Q2 2021 and fell as low as $8.2 million in Q4 2022.
• Historically, Current Deferred Revenue has averaged $46.5 million across 5 years, with a median of $58.3 million in 2024.
• On a YoY basis, Current Deferred Revenue climbed as much as 737.95% in 2023 and fell as far as 88.07% in 2023.
• Year by year, Current Deferred Revenue stood at $11.3 million in 2021, then declined by 27.46% to $8.2 million in 2022, then soared by 737.95% to $68.9 million in 2023, then dropped by 12.29% to $60.4 million in 2024, then slipped by 26.34% to $44.5 million in 2025.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $44.5 million in Q4 2025, $56.2 million in Q1 2025, and $60.4 million in Q4 2024.